From - A Hematology Oncology Wiki
Jump to navigation Jump to search

Note: Previous Treanda formulation discontinued on 2016-03-31 by Teva to switch to Bendeka.[1]

General information

Class/mechanism: Nitrogen mustard, alkylator; bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring which forms electrophilic alkyl groups, resulting in interstrand DNA crosslinks, leading to cell death via several pathways in both quiescent and dividing cells.[2][3][4][5][6][7]
Route: IV
Extravasation: irritant (usually), vesicant (rare)

For conciseness and simplicity, currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[2]

Diseases for which it is established (work in progress)

Diseases for which it is used

Patient drug information

History of changes in FDA indication

As Treanda:

As Bendeka:

History of changes in EMA indication

  • 2010-07-07: EURD

History of changes in Health Canada indication

  • 2012-08-24: Initial notice of compliance

History of changes in PMDA indication

Also known as

  • Code names: CEP-18083, SDX-105, SyB L-0501
  • Generic names: bendamustin hydrochloride, bendamustine hydrochloride, cytostasan hydrochloride
  • Brand names: Belrapzo, Bendamax, Bendawel, Bendeka, Bendit, Innomustine, Leuben, Levact, Maxtorin, MyMust, Purplz, Ribomustin, Treakisym, Treanda, Vivimusta, Xyotin